Too much processed meat and not enough fruits and whole grains are the leading risk factors for diet-related GI cancers.

A new blood test was found to detect colon cancer with more than 80% accuracy — and to rule it out for 90% of healthy people.

Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.

Researchers sought to determine trends and future patterns for liver, pancreatic, colorectal, stomach, and esophageal cancers in the US.

Researchers investigated immune-related adverse effects and characteristics that may predict their incidence in patients receiving ICIs for gastrointestinal cancers.

David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

highlighted the transformative role of personalized medicine in gastrointestinal (GI) cancer treatment through advances in next-generation sequencing and circulating tumor DNA, while emphasizing ...

Daily low-dose aspirin can help prevent cancers from returning in about a third of colon cancer patients, a new stu ...

Aspirin reduced recurrence by 50% in PIK3CA-mutated colorectal cancer, the DCISionRT test earned FDA breakthrough status for predicting radiotherapy benefit in DCIS, and nivolumab plus chemotherapy ...

UC Davis Health, a university hospital in Sacramento, California, has become the first customer to order the EndoDrill GI from Swedish medical device company BiBBInstruments. The product is intended ...

Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that ...